CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.65

15 Apr
2024

-0.050

OPEN

$2.76

-1.85%

HIGH

$2.76

504,639

LOW

$2.63

TARGET
$3.90 47.2% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A - 16.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx-9.5
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx-
Book Value Per Share xxxxxxxxxxxx26.5
Net Operating Cash Flow xxxxxxxxxxxx-27.5 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx-30.48 %
Return on Invested Capital xxxxxxxxxxxx-30.48 %
Return on Assets xxxxxxxxxxxx-27.84 %
Return on Equity xxxxxxxxxxxx-30.48 %
Return on Total Capital xxxxxxxxxxxx-44.81 %
Free Cash Flow ex dividends xxxxxxxxxxxx-27.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx-
Long Term Debt xxxxxxxxxxxx-
Total Debt xxxxxxxxxxxx-
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx65 M
Price To Book Value xxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx36 M
Research & Development xxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

19/02/2024

-1

No Rating

-

Management at Clarity Pharmaceuticals will now push for a Phase 3 trial -for detection of prostrate cancer lesions in patients with biochemical recurrence (BCR)- after initial positive findings from the Phase1/2 diagnostic trial, explains Morgans.

The trial results showed the treatment was broadly safe, observes the analyst, and show potential to detect earlier stage disease.

Clarity is within Morgans 'Keeping Stock' research designation, whereby no forecasts, target or rating are assigned.

CU6 STOCK CHART